VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily Gold Miners Bull 3X ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares UltraPro Short QQQ

Direxion Technology Bear 3X Shares

VanEck Vectors Junior Gold Miners ETF

ProShares Ultra Silver

VanEck Vectors Gold Miners ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

VS TR -1x Short VIX Futures ETF

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily Semicondct Bull 3X ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

ProShares UltraPro QQQ

Direxion Daily Technology Bull 3X ETF

ProShares UltraShort Silver

AXS 2X Innovation ETF

ProShares UltraShort Bloomberg Natrl Gas

Imunon Inc. Common Stock

Oklo Inc.

NuScale Power Corporation Class A Common Stock

ASP Isotopes Inc. Common Stock

Cameco Corporation Common Stock

SolarEdge Technologies Inc. Common Stock

Intuit Inc. Common Stock

CompoSecure Inc. Class A Common Stock

GameStop Corporation Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Siyata Mobile Inc. Common Shares

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

Navitas Semiconductor Corporation Common Stock

Trio Petroleum Corp. Common Stock

Workday Inc. Class A Common Stock

Copart Inc. (DE) Common Stock

Pony AI Inc. American Depositary Shares

Ross Stores Inc. Common Stock

MicroStrategy Incorporated Common Stock Class A

Cleveland-Cliffs Inc. Common Stock

Click here to get full coverage on Ardelyx CEO Mike Raab to Share Company Vision at Major Healthcare Conference 2025 - Stock Titan

Ardelyx CEO Mike Raab to Share Company Vision at Major Healthcare Conference 2025  Stock Titan

Ardelyx CEO Mike Raab to Share Company Vision at Major Healthcare Conference 2025 - Stock Titan

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX - PR Newswire

Click here to get full coverage on David Mott Bought 19% More Shares In Ardelyx - simplywall.st

David Mott Bought 19% More Shares In Ardelyx  simplywall.st

David Mott Bought 19% More Shares In Ardelyx - simplywall.st

Click here to get full coverage on Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates  Yahoo Finance

Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (NASDAQ:ARDX) - Seeking Alpha

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (NASDAQ:ARDX)  Seeking Alpha

Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty (NASDAQ:ARDX) - Seeking Alpha

Click here to get full coverage on Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 | ARDX Stock News - GuruFocus

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 | ARDX Stock News  GuruFocus

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 | ARDX Stock News - GuruFocus

Click here to get full coverage on Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders - ACCESS Newswire

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders  ACCESS Newswire

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ardelyx, Inc.(ARDX) Shareholders - ACCESS Newswire

Click here to get full coverage on $ARDX stock is up 3% today. Here's what we see in our data. - Nasdaq

$ARDX stock is up 3% today. Here's what we see in our data.  Nasdaq

$ARDX stock is up 3% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - TradingView

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025  TradingView

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - TradingView

Click here to get full coverage on Ardelyx CFO sells $29,459 in stock By Investing.com - Investing.com Nigeria

Ardelyx CFO sells $29,459 in stock By Investing.com  Investing.com Nigeria

Ardelyx CFO sells $29,459 in stock By Investing.com - Investing.com Nigeria

Click here to get full coverage on Tuesday 5/6 Insider Buying Report: ARDX, SON - Nasdaq

Tuesday 5/6 Insider Buying Report: ARDX, SON  Nasdaq

Tuesday 5/6 Insider Buying Report: ARDX, SON - Nasdaq

Click here to get full coverage on Ardelyx falls 14% as Q1 results miss on both lines (ARDX:NASDAQ) - Seeking Alpha

Ardelyx falls 14% as Q1 results miss on both lines (ARDX:NASDAQ)  Seeking Alpha

Ardelyx falls 14% as Q1 results miss on both lines (ARDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet - simplywall.st

Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet  simplywall.st

Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet - simplywall.st

Click here to get full coverage on Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? - Yahoo Finance

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?  Yahoo Finance

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last? - Yahoo Finance

Click here to get full coverage on Biotech Powerhouse: Ex-Gilead CMO Merdad Parsey Strengthens Ardelyx Board with 25-Year Expertise - Stock Titan

Biotech Powerhouse: Ex-Gilead CMO Merdad Parsey Strengthens Ardelyx Board with 25-Year Expertise  Stock Titan

Biotech Powerhouse: Ex-Gilead CMO Merdad Parsey Strengthens Ardelyx Board with 25-Year Expertise - Stock Titan

Click here to get full coverage on Ardelyx stock downgraded at Raymond James (ARDX:NASDAQ) - Seeking Alpha

Ardelyx stock downgraded at Raymond James (ARDX:NASDAQ)  Seeking Alpha

Ardelyx stock downgraded at Raymond James (ARDX:NASDAQ) - Seeking Alpha

Click here to get full coverage on Biotech Player Ardelyx Announces Q1 2025 Earnings Date: Financial Results and Business Updates Coming May 1 - Stock Titan

Biotech Player Ardelyx Announces Q1 2025 Earnings Date: Financial Results and Business Updates Coming May 1  Stock Titan

Biotech Player Ardelyx Announces Q1 2025 Earnings Date: Financial Results and Business Updates Coming May 1 - Stock Titan

Click here to get full coverage on Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say  Yahoo Finance

Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance

Click here to get full coverage on ARDX - Ardelyx Latest Stock News & Market Updates - Stock Titan

ARDX - Ardelyx Latest Stock News & Market Updates  Stock Titan

ARDX - Ardelyx Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Can Ardelyx Management Reveal New Growth Strategies at These Three March Healthcare Conferences? - Stock Titan

Can Ardelyx Management Reveal New Growth Strategies at These Three March Healthcare Conferences?  Stock Titan

Can Ardelyx Management Reveal New Growth Strategies at These Three March Healthcare Conferences? - Stock Titan

Click here to get full coverage on Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?  Yahoo Finance

Why Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now? - Yahoo Finance

Click here to get full coverage on Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?  Yahoo Finance

Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Click here to get full coverage on Ardelyx Executives Sell Shares to Cover Taxes - TradingView

Ardelyx Executives Sell Shares to Cover Taxes  TradingView

Ardelyx Executives Sell Shares to Cover Taxes - TradingView

Click here to get full coverage on Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics  Yahoo Finance

Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance

Click here to get full coverage on First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan

First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results  Stock Titan

First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan

Click here to get full coverage on Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade) (ARDX) - Seeking Alpha

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade) (ARDX)  Seeking Alpha

Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade) (ARDX) - Seeking Alpha

Click here to get full coverage on (ARDX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

(ARDX) Technical Pivots with Risk Controls  news.stocktradersdaily.com

(ARDX) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky - ACCESS Newswire

ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky  ACCESS Newswire

ATTENTION ARDX Investors: Securities Fraud Investigation Underway - Contact Levi & Korsinsky - ACCESS Newswire

Click here to get full coverage on Ardelyx (ARDX) Sees Revenue Surge in Q1 2025 - GuruFocus

Ardelyx (ARDX) Sees Revenue Surge in Q1 2025  GuruFocus

Ardelyx (ARDX) Sees Revenue Surge in Q1 2025 - GuruFocus

Click here to get full coverage on Can Ardelyx's $334M Revenue and Dual Blockbuster Strategy Transform Biotech Investment? - Stock Titan

Can Ardelyx's $334M Revenue and Dual Blockbuster Strategy Transform Biotech Investment?  Stock Titan

Can Ardelyx's $334M Revenue and Dual Blockbuster Strategy Transform Biotech Investment? - Stock Titan

Click here to get full coverage on Ardelyx (ARDX) Sees Its Depressed Stock Turning Around - Nasdaq

Ardelyx (ARDX) Sees Its Depressed Stock Turning Around  Nasdaq

Ardelyx (ARDX) Sees Its Depressed Stock Turning Around - Nasdaq

Click here to get full coverage on Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025 - Stock Titan

Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025  Stock Titan

Triple Study Results: IBSRELA IBS-C Drug Proves Safe for Teens and Nursing Mothers at DDW 2025 - Stock Titan

Click here to get full coverage on Ardelyx (ARDX) Meets Q4 Earnings Estimates - Yahoo Finance

Ardelyx (ARDX) Meets Q4 Earnings Estimates  Yahoo Finance

Ardelyx (ARDX) Meets Q4 Earnings Estimates - Yahoo Finance

Click here to get full coverage on Breakthrough: New Analysis Reveals Better Outcomes for First-in-Class Kidney Drug XPHOZAH - Stock Titan

Breakthrough: New Analysis Reveals Better Outcomes for First-in-Class Kidney Drug XPHOZAH  Stock Titan

Breakthrough: New Analysis Reveals Better Outcomes for First-in-Class Kidney Drug XPHOZAH - Stock Titan

Click here to get full coverage on Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates - Stock Titan

Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates  Stock Titan

Ardelyx Reports Strong 2024: IBSRELA, XPHOZAH Drive $319M Revenue as Growth Accelerates - Stock Titan

Click here to get full coverage on Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX) - Seeking Alpha

Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX)  Seeking Alpha

Ardelyx: A Small Bet Its Latest Setback Will Be Temporary (NASDAQ:ARDX) - Seeking Alpha

Click here to get full coverage on Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Diseas - GuruFocus

Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Diseas  GuruFocus

Ardelyx (ARDX) Highlights IBSRELA's Efficacy at Digestive Diseas - GuruFocus

Click here to get full coverage on Earnings call transcript: Ardelyx Inc Q1 2025 sees stock drop after earnings miss - Investing.com

Earnings call transcript: Ardelyx Inc Q1 2025 sees stock drop after earnings miss  Investing.com

Earnings call transcript: Ardelyx Inc Q1 2025 sees stock drop after earnings miss - Investing.com

Click here to get full coverage on Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount - Stock Titan

Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount  Stock Titan

Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount - Stock Titan

Click here to get full coverage on Oncology Institute And 2 Other Promising Penny Stocks To Watch - simplywall.st

Oncology Institute And 2 Other Promising Penny Stocks To Watch  simplywall.st

Oncology Institute And 2 Other Promising Penny Stocks To Watch - simplywall.st

Click here to get full coverage on Class Action Lawsuit Against Ardelyx, Inc. (NASDAQ:ARDX) - Nasdaq

Class Action Lawsuit Against Ardelyx, Inc. (NASDAQ:ARDX)  Nasdaq

Class Action Lawsuit Against Ardelyx, Inc. (NASDAQ:ARDX) - Nasdaq

Click here to get full coverage on Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | AR - GuruFocus

Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | AR  GuruFocus

Ardelyx (ARDX) Price Target Reduced by Citi After Q1 Report | AR - GuruFocus

Click here to get full coverage on Ardelyx (ARDX) Shares Drop 14% After Q1 Earnings Miss - GuruFocus

Ardelyx (ARDX) Shares Drop 14% After Q1 Earnings Miss  GuruFocus

Ardelyx (ARDX) Shares Drop 14% After Q1 Earnings Miss - GuruFocus

Click here to get full coverage on (ARDX) Proactive Strategies - news.stocktradersdaily.com

(ARDX) Proactive Strategies  news.stocktradersdaily.com

(ARDX) Proactive Strategies - news.stocktradersdaily.com

Click here to get full coverage on Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?  Insider Monkey

Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Click here to get full coverage on Ardelyx director David Mott buys $388,738 in common stock - Investing.com

Ardelyx director David Mott buys $388,738 in common stock  Investing.com

Ardelyx director David Mott buys $388,738 in common stock - Investing.com

Click here to get full coverage on Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com India

Ardelyx chief medical officer sells shares worth $26,206 By Investing.com  Investing.com India

Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com India

Click here to get full coverage on Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com Nigeria

Ardelyx chief medical officer sells shares worth $26,206 By Investing.com  Investing.com Nigeria

Ardelyx chief medical officer sells shares worth $26,206 By Investing.com - Investing.com Nigeria

Click here to get full coverage on Ardelyx appoints new board member, grants equity awards - Investing.com

Ardelyx appoints new board member, grants equity awards  Investing.com

Ardelyx appoints new board member, grants equity awards - Investing.com

Click here to get full coverage on Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It (NASDAQ:ARDX) - Seeking Alpha

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It (NASDAQ:ARDX)  Seeking Alpha

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It (NASDAQ:ARDX) - Seeking Alpha

Click here to get full coverage on Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com

Ardelyx stock hits 52-week low at $4.29 amid challenges  Investing.com

Ardelyx stock hits 52-week low at $4.29 amid challenges - Investing.com

Click here to get full coverage on Ardelyx CEO Michael Raab sells $191k in stock - Investing.com

Ardelyx CEO Michael Raab sells $191k in stock  Investing.com

Ardelyx CEO Michael Raab sells $191k in stock - Investing.com

Click here to get full coverage on Hedge Fund and Insider Trading News: Paul Tudor Jones, Warren Buffett, John Paulson Bill Ackman, Platinum Asset Management, Ardelyx Inc (ARDX), Stem Inc (STEM), and More - Insider Monkey

Hedge Fund and Insider Trading News: Paul Tudor Jones, Warren Buffett, John Paulson Bill Ackman, Platinum Asset Management, Ardelyx Inc (ARDX), Stem Inc (STEM), and More  Insider Monkey

Hedge Fund and Insider Trading News: Paul Tudor Jones, Warren Buffett, John Paulson Bill Ackman, Platinum Asset Management, Ardelyx Inc (ARDX), Stem Inc (STEM), and More - Insider Monkey

Click here to get full coverage on Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - Seeking Alpha

Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update)  Seeking Alpha

Ardelyx Inc (ARDX)

Price Chart

Key Statistics

Technicals

About ARDX

Latest News

Ardelyx CEO Mike Raab to Share Company Vision at Major Healthcare Conference 2025 - Stock Titan

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX - PR Newswire

David Mott Bought 19% More Shares In Ardelyx - simplywall.st

Advanced Charts

Top Gainers

Top Losers